-
1
-
-
0015990773
-
A new anticancer drug with significant clinical activity
-
Blum R.H., Carter Adriamycin S.K. A new anticancer drug with significant clinical activity. Ann Intern Med 1974, 80:249-259.
-
(1974)
Ann Intern Med
, vol.80
, pp. 249-259
-
-
Blum, R.H.1
Carter Adriamycin, S.K.2
-
2
-
-
0015849162
-
A clinicopathologic analysis of adriamycin cardiotoxicity
-
Lefrak E.A., Pitha J., Rosenheim S., et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
-
(1973)
Cancer
, vol.32
, pp. 302-314
-
-
Lefrak, E.A.1
Pitha, J.2
Rosenheim, S.3
-
3
-
-
0015643470
-
Adriamycin-an antitumor antibiotic in the treatment of neoplastic diseases
-
Tan C., Etcubanas E., Wollner N., et al. Adriamycin-an antitumor antibiotic in the treatment of neoplastic diseases. Cancer 1973, 32:9-17.
-
(1973)
Cancer
, vol.32
, pp. 9-17
-
-
Tan, C.1
Etcubanas, E.2
Wollner, N.3
-
4
-
-
0018716636
-
Risk factors for doxorubicin-induced congestive heart failure
-
Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710-717.
-
(1979)
Ann Intern Med
, vol.91
, pp. 710-717
-
-
Von Hoff, D.D.1
Layard, M.W.2
Basa, P.3
-
5
-
-
0017354816
-
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
-
Von Hoff D.D., Rozencweig M., Layard M., et al. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977, 62:200-208.
-
(1977)
Am J Med
, vol.62
, pp. 200-208
-
-
Von Hoff, D.D.1
Rozencweig, M.2
Layard, M.3
-
6
-
-
28744446343
-
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the Interna
-
Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
-
(2005)
Circulation
, vol.112
-
-
Hunt, S.A.1
Abraham, W.T.2
Chin, M.H.3
-
7
-
-
0038521374
-
Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials
-
Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
-
(2003)
Cancer
, vol.97
, pp. 2869-2879
-
-
Swain, S.M.1
Whaley, F.S.2
Ewer, M.S.3
-
8
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
9
-
-
0022622814
-
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy
-
Torti F.M., Bristow M.M., Lum B.L., et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 1986, 46:3722-3727.
-
(1986)
Cancer Res
, vol.46
, pp. 3722-3727
-
-
Torti, F.M.1
Bristow, M.M.2
Lum, B.L.3
-
10
-
-
0035985273
-
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients
-
Jensen B.V., Skovsgaard T., Nielsen S.L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002, 13:699-709.
-
(2002)
Ann Oncol
, vol.13
, pp. 699-709
-
-
Jensen, B.V.1
Skovsgaard, T.2
Nielsen, S.L.3
-
11
-
-
0031734394
-
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer
-
Ryberg M., Nielsen D., Skovsgaard T., et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998, 16:3502-3508.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3502-3508
-
-
Ryberg, M.1
Nielsen, D.2
Skovsgaard, T.3
-
12
-
-
42749100219
-
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
-
CD005006
-
van Dalen E.C., Michiels E.M., Caron H.N., et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2006, 4. CD005006.
-
(2006)
Cochrane Database Syst Rev
, vol.4
-
-
van Dalen, E.C.1
Michiels, E.M.2
Caron, H.N.3
-
13
-
-
0026042237
-
A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors
-
Casper E.S., Gaynor J.J., Hajdu S.I., et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991, 68:1221-1229.
-
(1991)
Cancer
, vol.68
, pp. 1221-1229
-
-
Casper, E.S.1
Gaynor, J.J.2
Hajdu, S.I.3
-
14
-
-
42749107115
-
Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy
-
CD005008
-
van Dalen E.C., van der Pal H.J., Caron H.N., et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2006, 4. CD005008.
-
(2006)
Cochrane Database Syst Rev
, vol.4
-
-
van Dalen, E.C.1
van der Pal, H.J.2
Caron, H.N.3
-
15
-
-
3042850886
-
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia
-
Lipshultz S.E., Rifai N., Dalton V.M., et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004, 351:145-153.
-
(2004)
N Engl J Med
, vol.351
, pp. 145-153
-
-
Lipshultz, S.E.1
Rifai, N.2
Dalton, V.M.3
-
16
-
-
80052044499
-
Cardioprotective interventions for cancer patients receiving anthracyclines
-
CD003917
-
van Dalen E.C., Caron H.N., Dickinson H.O., et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005, 1. CD003917.
-
(2005)
Cochrane Database Syst Rev
, vol.1
-
-
van Dalen, E.C.1
Caron, H.N.2
Dickinson, H.O.3
-
17
-
-
28044442932
-
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone
-
Nakamae H., Tsumura K., Terada Y., et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005, 104:2492-2498.
-
(2005)
Cancer
, vol.104
, pp. 2492-2498
-
-
Nakamae, H.1
Tsumura, K.2
Terada, Y.3
-
18
-
-
3042698689
-
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults
-
Hequet O., Le Q.H., Moullet I., et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004, 22:1864-1871.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1864-1871
-
-
Hequet, O.1
Le, Q.H.2
Moullet, I.3
-
19
-
-
49249105457
-
Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma
-
Hershman D.L., McBride R.B., Eisenberger A., et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:3159-3165.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3159-3165
-
-
Hershman, D.L.1
McBride, R.B.2
Eisenberger, A.3
-
20
-
-
0031792641
-
Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients
-
Shapiro C.L., Hardenbergh P.H., Gelman R., et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998, 16:3493-3501.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3493-3501
-
-
Shapiro, C.L.1
Hardenbergh, P.H.2
Gelman, R.3
-
21
-
-
0025850827
-
Cardiac toxicity 4 to 20 years after completing anthracycline therapy
-
Steinherz L.J., Steinherz P.G., Tan C.T., et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991, 266:1672-1677.
-
(1991)
JAMA
, vol.266
, pp. 1672-1677
-
-
Steinherz, L.J.1
Steinherz, P.G.2
Tan, C.T.3
-
22
-
-
3342905435
-
Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy
-
Pein F., Sakiroglu O., Dahan M., et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004, 91:37-44.
-
(2004)
Br J Cancer
, vol.91
, pp. 37-44
-
-
Pein, F.1
Sakiroglu, O.2
Dahan, M.3
-
23
-
-
34548533485
-
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer
-
Pinder M.C., Duan Z., Goodwin J.S., et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007, 25:3808-3815.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3808-3815
-
-
Pinder, M.C.1
Duan, Z.2
Goodwin, J.S.3
-
24
-
-
32144448027
-
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment
-
Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7820-7826
-
-
Ewer, M.S.1
Vooletich, M.T.2
Durand, J.B.3
-
25
-
-
33748642331
-
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience
-
Guarneri V., Lenihan D.J., Valero V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006, 24:4107-4115.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4107-4115
-
-
Guarneri, V.1
Lenihan, D.J.2
Valero, V.3
-
26
-
-
34548152541
-
Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility
-
Telli M.L., Hunt S.A., Carlson R.W., et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007, 25:3525-3533.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3525-3533
-
-
Telli, M.L.1
Hunt, S.A.2
Carlson, R.W.3
-
27
-
-
66249091930
-
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine
-
Ross J.S., Slodkowska E.A., Symmans W.F., et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
-
(2009)
Oncologist
, vol.14
, pp. 320-368
-
-
Ross, J.S.1
Slodkowska, E.A.2
Symmans, W.F.3
-
28
-
-
0036099675
-
ErbB2 is essential in the prevention of dilated cardiomyopathy
-
Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002, 8:459-465.
-
(2002)
Nat Med
, vol.8
, pp. 459-465
-
-
Crone, S.A.1
Zhao, Y.Y.2
Fan, L.3
-
29
-
-
0028884413
-
Requirement for neuregulin receptor erbB2 in neural and cardiac development
-
Lee K.F., Simon H., Chen H., et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995, 378:394-398.
-
(1995)
Nature
, vol.378
, pp. 394-398
-
-
Lee, K.F.1
Simon, H.2
Chen, H.3
-
30
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
31
-
-
36849016904
-
Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→ paclitaxel (T) vs AC→ T with trastuzumab (H) Chicago, IL, [abstract]
-
Abstract LBA513
-
Rastogi P., Jeong J., Geyer C.E., et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→ paclitaxel (T) vs AC→ T with trastuzumab (H) Chicago, IL, [abstract]. J Clin Oncol 2007, 25(Suppl 1). Abstract LBA513.
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL 1
-
-
Rastogi, P.1
Jeong, J.2
Geyer, C.E.3
-
32
-
-
38149097872
-
Highlights of the 2007 Scientific Meeting of the Heart Failure Society of America. Washington, DC, September 16-19, 2007
-
Mehra M.R., Rockman H.A., Greenberg B.H. Highlights of the 2007 Scientific Meeting of the Heart Failure Society of America. Washington, DC, September 16-19, 2007. J Am Coll Cardiol 2008, 51:320-327.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 320-327
-
-
Mehra, M.R.1
Rockman, H.A.2
Greenberg, B.H.3
-
33
-
-
29744442709
-
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
-
Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23:7811-7819.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7811-7819
-
-
Tan-Chiu, E.1
Yothers, G.2
Romond, E.3
-
34
-
-
33845914783
-
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
-
Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
-
(2007)
Lancet
, vol.369
, pp. 29-36
-
-
Smith, I.1
Procter, M.2
Gelber, R.D.3
-
35
-
-
34548531901
-
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
-
Suter T.M., Procter M., van Veldhuisen D.J., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007, 25:3859-3865.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3859-3865
-
-
Suter, T.M.1
Procter, M.2
van Veldhuisen, D.J.3
-
36
-
-
84857112700
-
-
BCIRG 006: Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. 2006. Available at: Accessed January 14, 2009.
-
Slamon D, Eiermann W, Robert N, et-al. BCIRG 006: Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. 2006. Available at: Accessed January 14, 2009. http://wwwbcirgorg/NR/rdonlyres/eqkdodg2dy7t557o7s6uvj7ytpe6gcfg5gmh2ely6hnhh5pjlabz3nd6jddlnao7qoikej3edohsijyiisfvp367uuc/BCIRG006%2b2nd%2bInterim%2bAnalysispdf.
-
-
-
Slamon, D.1
Eiermann, W.2
Robert, N.3
-
37
-
-
33645720799
-
Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide with docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study
-
Slamon D.J., Eiermann W., Robert N., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide with docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005, 94:S5.
-
(2005)
Breast Cancer Res Treat
, vol.94
-
-
Slamon, D.J.1
Eiermann, W.2
Robert, N.3
-
38
-
-
34548481766
-
111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity
-
de Korte M.A., de Vries E.G., Lub-de Hooge M.N., et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007, 43:2046-2051.
-
(2007)
Eur J Cancer
, vol.43
, pp. 2046-2051
-
-
de Korte, M.A.1
de Vries, E.G.2
Lub-de Hooge, M.N.3
-
39
-
-
33744831505
-
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
-
Perik P.J., Lub-De Hooge M.N., Gietema J.A., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006, 24:2276-2282.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2276-2282
-
-
Perik, P.J.1
Lub-De Hooge, M.N.2
Gietema, J.A.3
-
40
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
-
(2006)
N Engl J Med
, vol.355
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
-
41
-
-
77949884661
-
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
-
Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1124-1130
-
-
Blackwell, K.L.1
Burstein, H.J.2
Storniolo, A.M.3
-
42
-
-
73149115341
-
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
-
Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5538-5546
-
-
Johnston, S.1
Pippen, J.2
Pivot, X.3
-
43
-
-
0035993035
-
Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy
-
Toko H., Oka T., Zou Y., et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 2002, 25:597-603.
-
(2002)
Hypertens Res
, vol.25
, pp. 597-603
-
-
Toko, H.1
Oka, T.2
Zou, Y.3
-
44
-
-
0042198675
-
B-type natriuretic peptide in cardiovascular disease
-
de Lemos J.A., McGuire D.K., Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362:316-322.
-
(2003)
Lancet
, vol.362
, pp. 316-322
-
-
de Lemos, J.A.1
McGuire, D.K.2
Drazner, M.H.3
-
45
-
-
0033822124
-
Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction
-
Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000, 21:1502-1513.
-
(2000)
Eur Heart J
, vol.21
, pp. 1502-1513
-
-
-
46
-
-
2942522528
-
Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy
-
Cardinale D., Sandri M.T., Colombo A., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004, 109:2749-2754.
-
(2004)
Circulation
, vol.109
, pp. 2749-2754
-
-
Cardinale, D.1
Sandri, M.T.2
Colombo, A.3
-
47
-
-
33845402341
-
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
-
Cardinale D., Colombo A., Sandri M.T., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114:2474-2481.
-
(2006)
Circulation
, vol.114
, pp. 2474-2481
-
-
Cardinale, D.1
Colombo, A.2
Sandri, M.T.3
-
48
-
-
33845206791
-
Protective effects of carvedilol against anthracycline-induced cardiomyopathy
-
Kalay N., Basar E., Ozdogru I., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006, 48:2258-2262.
-
(2006)
J Am Coll Cardiol
, vol.48
, pp. 2258-2262
-
-
Kalay, N.1
Basar, E.2
Ozdogru, I.3
-
49
-
-
15744395079
-
UK audit of left ventricular ejection fraction estimation from equilibrium ECG gated blood pool images
-
Skrypniuk J.V., Bailey D., Cosgriff P.S., et al. UK audit of left ventricular ejection fraction estimation from equilibrium ECG gated blood pool images. Nucl Med Commun 2005, 26:205-215.
-
(2005)
Nucl Med Commun
, vol.26
, pp. 205-215
-
-
Skrypniuk, J.V.1
Bailey, D.2
Cosgriff, P.S.3
-
50
-
-
0035370698
-
Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study
-
Wassmuth R., Lentzsch S., Erdbruegger U., et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. Am Heart J 2001, 141:1007-1013.
-
(2001)
Am Heart J
, vol.141
, pp. 1007-1013
-
-
Wassmuth, R.1
Lentzsch, S.2
Erdbruegger, U.3
-
51
-
-
33746849860
-
Troponin I and cardiovascular risk stratification in patients with testicular cancer
-
[author reply: 3508-9]
-
Cardinale D., Lamantia G., Cipolla C.M. Troponin I and cardiovascular risk stratification in patients with testicular cancer. J Clin Oncol 2006, 24:3508. [author reply: 3508-9].
-
(2006)
J Clin Oncol
, vol.24
, pp. 3508
-
-
Cardinale, D.1
Lamantia, G.2
Cipolla, C.M.3
-
52
-
-
0035985276
-
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
-
Cardinale D., Sandri M.T., Martinoni A., et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002, 13:710-715.
-
(2002)
Ann Oncol
, vol.13
, pp. 710-715
-
-
Cardinale, D.1
Sandri, M.T.2
Martinoni, A.3
-
53
-
-
0033855860
-
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
-
Cardinale D., Sandri M.T., Martinoni A., et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000, 36:517-522.
-
(2000)
J Am Coll Cardiol
, vol.36
, pp. 517-522
-
-
Cardinale, D.1
Sandri, M.T.2
Martinoni, A.3
|